Application 211468
- Type
- ANDA
- Sponsor
- AUROBINDO PHARMA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DAPAGLIFLOZIN | DAPAGLIFLOZIN | TABLET;ORAL | 5MG | No | No |
| 002 | DAPAGLIFLOZIN | DAPAGLIFLOZIN | TABLET;ORAL | 10MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211468-001 | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | |
| A211468-002 | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A211468-001 | AB |
| A211468-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A211468-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A211468-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A211468-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A211468-002 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dapagliflozin | DAPAGLIFLOZIN | Aurobindo Pharma Limited | f56593f7-588e-489d-9fad-b459e90dab18 | 2026-07-17 | Warnings, Adverse reactions | 211468 ANDA211468 |
| Dapagliflozin | DAPAGLIFLOZIN | A-S Medication Solutions | addc6ead-f9e3-4b40-aed1-bc008a5c9b0f | 2026-05-18 | Warnings, Adverse reactions | 211468 ANDA211468 |
| Dapagliflozin | DAPAGLIFLOZIN | A-S Medication Solutions | c4264ff6-5199-49e9-91d3-3ad67b42f88d | 2026-05-18 | Warnings, Adverse reactions | 211468 ANDA211468 |